Table 1.
Summary of device type, imaging modality and recanalisation in the eight trials.
| Primary author; study name | Device type | Advanced imaginga | Recanalisation % |
|---|---|---|---|
| Berkhemer et al.: MR CLEAN8 | Trevo retrievable stents and others | No | MT treatment group = 115/196 (59) |
| Campbell et al.: EXTEND:IA31 | Solitaire FR retrievable stent | CT perfusion imaging | IV rt-PA plus MT = 25/35 (86) |
| Goyal et al.: ESCAPE32 | Retrievable stents or aspiration | Yes | IV rt-PA plus MT = 113/156 (72) |
| Jovin et al.: REVASCAT33 | Solitaire FR | Y (in defined subgroups) | IV rt-PA within 4.5 h plus MT = 67/103 (65) |
| Saver et al.: SWIFT PRIME34 | Solitaire FR or Solitaire 2 | Y (in a majority) | IV-tPA plus MT = 73/83 (88) |
| Mocco et al.: THERAPY12 | Penumbra, Solitaire or Trevo | No | IV rt-PA plus MT = 30/43 (70) |
| Bracard et al.: THRACE13 | Merci, Penumbra, Catch, Solitaire | Y (MRI in a majority) | IV rt-PA plus MT = 95/138 (69) |
| Muir et al.: PISTE14 | Any CE-marked device approved for MT (stentrievers or aspiration) | No | IV rt-PA plus MT = 26/30 (87) |
CT: computed tomography; IV: intravenous; MRI: magnetic resonance imaging; MT: mechanical thrombectomy; rt-PA: recombinant tissue plasminogen activator.
a
Advanced imaging is taken as use of MRI techniques, perfusion CT or a systematic combination of CTA collateral scoring and ASPECTS on CT brain (ESCAPE trial).